Results of the ONTARGET and TRANSCEND studies: an update and discussion. - Wikidata - awgldk - TriplyDB

Results of the ONTARGET and TRANSCEND studies: an update and discussion.

Results of the ONTARGET and TRANSCEND studies: an update and discussion.

http://www.wikidata.org/entity/Q37167526

about

PPARs: Protectors or Opponents of Myocardial Function?Carotid artery intima-media thickness and the renin-angiotensin system Doxycycline, a matrix metalloprotease inhibitor, reduces vascular remodeling and damage after cerebral ischemia in stroke-prone spontaneously hypertensive rats.Cardio classics revisited--focus on the role of candesartan.Angiotensin receptor blockers and risk of dementia: cohort study in UK Clinical Practice Research Datalink.Metabolic effect of combined telmisartan and nifedipine CR therapy in patients with essential hypertension.Role of the renin angiotensin system in diabetic nephropathy.

P2860

Q26771753-CAFAD5C6-23F9-4813-81FC-60F8BD07F9BC Q26851516-33ADA77E-32CB-430C-93CB-90987173E757 Q33892142-BAA90E89-E755-46BA-AA71-252BBA70F8CE Q34417462-BD28D1CF-BF37-4CB4-89D0-0A0CB32DF15A Q35023755-9DB44591-4514-484F-AEC4-F7E798F1568D Q41835562-C8914FF2-1651-4248-848D-E6B8F97ED0EC Q42723231-D56EC377-855E-4E56-978A-6DE516C23BBB

P2860

Results of the ONTARGET and TRANSCEND studies: an update and discussion.

http://www.wikidata.org/entity/Q37167526

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 08 April 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Results of the ONTARGET and TRANSCEND studies: an update and discussion.

@en

Results of the ONTARGET and TRANSCEND studies: an update and discussion.

@nl

type

label

Results of the ONTARGET and TRANSCEND studies: an update and discussion.

@en

Results of the ONTARGET and TRANSCEND studies: an update and discussion.

@nl

prefLabel

Results of the ONTARGET and TRANSCEND studies: an update and discussion.

@en

Results of the ONTARGET and TRANSCEND studies: an update and discussion.

@nl

P1433

Q37167526-778289E3-FDC3-4817-8E3F-9B0C69AD62A5

P1476

Q37167526-67C1129C-5A2B-4318-B79A-93BF1012AA61

P2093

Q37167526-4558FEB6-BC0A-4BF4-8B4A-FC1D9227EBBC

P2860

Q37167526-0F60619C-1BED-4906-B00C-5B58333A4479

Q37167526-0F7C860D-2D59-4A71-B0ED-387F54CCCB0F

Q37167526-110A7C98-CF4D-47F9-AFA8-A1A26B469011

Q37167526-2A553AE4-4CE2-4A28-98BB-8797FEB3F757

Q37167526-31E00A6C-B195-4BE8-B2D7-9D8E0298B0A3

Q37167526-3AA5AE4F-8306-4085-A61C-91853F4329E5

Q37167526-3F5E9391-1E24-41FE-A9A6-D0B1932E3512

Q37167526-42FC9534-15E3-44E1-809D-14AAE270A4F1

Q37167526-4916FE05-08BA-4111-9F80-03F8E94BC527

Q37167526-4A2D8E33-62FF-4C15-8831-4339EA1C1394

P304

Q37167526-FCAD8E2B-97AE-4717-AB77-B72AA5D09496

P31

Q37167526-3B850637-71FE-4FE4-AABF-86C461B38491

P407

Q37167526-90234B6C-E4B6-4330-921B-AE74037A8808

P433

Q37167526-05808F54-5D24-48EC-8C91-ACCFBFEA7735

P478

Q37167526-EE33B94B-AB71-4458-8FCC-030F501013F6

P577

Q37167526-EE463621-5DF9-49CB-884E-FB68AEB9C45F

P698

Q37167526-E6E771F0-3305-47CE-AE08-9A3327B463A4

P921

Q37167526-52C92E3A-F3FE-41BF-AEB4-2DDB4F13A9FB

Q37167526-A6B6BBBD-650F-4B34-A6DC-D1B2C9EE9FA1

Q37167526-A9C62B6A-FDE6-4756-B222-AE72BDDAC75D

P932

Q37167526-7B34108A-1CC2-4757-8CE4-AB811A641655

P1433

Vascular Health and Risk Management

P1476

Results of the ONTARGET and TRANSCEND studies: an update and discussion

@en

P2093

David Fitchett

http://www.w3.org/2001/XMLSchema#string

P2860

Angiotensin II increases human monocyte matrix metalloproteinase-1 through the AT2 receptor and prostaglandin E2: implications for atherosclerotic plaque rupture

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group.

Telmisartan, ramipril, or both in patients at high risk for vascular events.

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.

P304

21-29

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2009-04-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19436659

http://www.w3.org/2001/XMLSchema#string

P921

mechanism of action

cardiovascular disease

biomedical investigative technique

P932

2672448

http://www.w3.org/2001/XMLSchema#string